In Brief: Instromedix' LifeSigns
This article was originally published in The Gray Sheet
Instromedix' LifeSigns: Home-based patient monitoring system clears FDA, the Hillsboro, Oregon-based firm reports. The system is indicated for stabilized patients who may have compensated congestive heart failure, a history of myocardial infarction, symptoms of coronary artery disease, cardiac arrhythmias, conditions requiring Sp02 and high blood pressure monitoring and post-op cardiac recovery. Components of the system, which collects and transmits patient data to a medical facility via a standard telephone line, include the Shuttle, a portable patient monitor; the Commander, a telecommunications port for direct communication between patient and physician during data transfer; and the Central Station, a computerized patient management program...
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.
Alvogen believes it is the first company to file for a generic pazopanib rival to Novartis’ Votrient oncology brand in Europe.